CMB’s do not predict 3-month death or disability in intracerebral hemorrhage (ICH)

A secondary analysis of the ATACH-2 randomized clinical trial

Cerebral microbleeds (CMBs) are not associated with greater hematoma expansion, death, or disability at 3 months in patients with intracerebral hemorrhage (ICH) compared with patients with ICH without CMBs. In addition, CMBs do not significantly affect response to intensive blood pressure (BP) lowering therapy in these patients. This was reported in a study published in JAMA Neurology.


Clinical trial
Investigators performed a preplanned secondary analysis of the open-label, randomized Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 (ATACH-2) study, specifically on the magnetic resonance images obtained during the intensive BP lowering portion of the trial. In this trial, a total of 1000 eligible participants with ICH volumes <60 mL and a Glasgow Coma Scale score ≥5 at baseline were randomly assigned (1:1) to a systolic BP target of 110 to 139 mm Hg (intensive treatment) vs a BP target of 140 to 179 mm Hg (standard treatment) with intravenous nicardipine hydrochloride.

A total of 167 participants with CMBs (n = 120) and no CMBs (n = 47) were included in this secondary analysis. Death or disability at 3 months comprised the primary outcome, whereas the secondary outcome included a ≥33% expansion in hematoma volume, as assessed by a computed tomography scan.

No significantly lower risk

The primary outcome of death or disability (modified Rankin Scale score ≥4) was observed in 46 (29.3%) of 157 patients during the mean follow-up of 92.3 days. The same proportion of patients with CMBs and without CMBs experienced the primary outcome during follow-up (29.3% vs 29.3%, respectively). An analysis that adjusted for treatment group, baseline Glasgow Coma Scale score, age, and other covariates found that patients with CMBs did not have an increased risk for death or disability (adjusted relative risk [aRR], 0.83; 95% CI, 0.40-1.71; P =.61). In addition, patients with CMBs did not demonstrate a significantly lower risk for hematoma volume expansion (RR, 1.00; 95% CI, 0.42-2.39; P =.99).

The risk for the primary outcome was also similar among participants with CMBs who were randomly assigned to intensive vs standard acute BP lowering therapy (crude RR, 1.19; 95% CI, 0.61-2.33; P =.61), with no significant difference observed among non-CMB patients (crude RR, 1.42; 95% CI, 0.43-4.70; P =.57). Hematoma volume expansion rates were also similar among CMB (crude RR, 0.54; 95% CI, 0.22-1.34; P =.18) and non-CMB (crude RR, 1.00; 95% CI, 0.24-4.18; P =1.00) participants assigned to intensive BP lowering.



Source: NeurologyAdvisor | May 11, 2018

Leave a Reply

Your email address will not be published. Required fields are marked *